BTK and COVID-19: The mechanisms underlying the activity of BTK inhibitors in improving hypoxia in patients with severe COVID-19 seem to be mediated by an inhibition of exaggerated monocyte autophosphorylation and reduction in interleukin (IL)-6 production.